An overview of anti-Chikungunya antibody response in natural infection and vaccine-mediated immunity, including anti-CHIKV vaccine candidates and monoclonal antibodies targeting diverse epitopes on the viral envelope

Chandley, Pankaj; Lukose, Asha; Kumar, Rajesh; Rohatgi, Soma

doi:10.1016/j.microb.2023.100018

Cited by 2 publications

(6 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the role of PCR is highlighted for confirming CHIKV infections. These comprehensive evaluations provide insights into the effectiveness and protective capacity of CHIKV vaccines, emphasizing the importance of a robust and multifaceted immune response for successful vaccine development [91].…”

Section: Methodsmentioning

confidence: 99%

Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials

Rao,

Erku,

Mahalingam

et al. 2024

Journal of General Virology

View full text Add to dashboard Cite

Background. Chikungunya virus (CHIKV) causes chikungunya fever and has been responsible for major global epidemics of arthritic disease over the past two decades. Multiple CHIKV vaccine candidates are currently undergoing or have undergone human clinical trials, with one vaccine candidate receiving FDA approval. This scoping review was performed to evaluate the ‘efficacy’, ‘safety’ and ‘duration of protection’ provided by CHIKV vaccine candidates in human clinical trials. Methods. This scoping literature review addresses studies involving CHIKV vaccine clinical trials using available literature on the PubMed, Medline Embase, Cochrane Library and Clinicaltrial.gov databases published up to 25 August 2023. Covidence software was used to structure information and review the studies included in this article. Results. A total of 1138 studies were screened and, after removal of duplicate studies, 12 relevant studies were thoroughly reviewed to gather information. This review summarizs that all seven CHIKV vaccine candidates achieved over 90 % seroprotection against CHIKV after one or two doses. All vaccines were able to provide neutralizing antibody protection for at least 28 days. Conclusions. A variety of vaccine technologies have been used to develop CHIKV vaccine candidates. With one vaccine candidate having recently received FDA approval, it is likely that further CHIKV vaccines will be available commercially in the near future.

show abstract

Section: Methodsmentioning

confidence: 99%

Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials

Rao,

Erku,

Mahalingam

et al. 2024

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…(5-II) The protection afforded by antibodies could be attributed to their capacity to neutralise CHIKV directly and to induce other protective immune responses, such as antibodydependent and complement-mediated cellular cytotoxicity [21,46]. Effective protection against persistent arthritis in natural CHIKV infection involves crucial contributions from IgG antibodies, particularly IgG3 for neutralisation, while IgM complements IgG in immune responses; however, a discrepancy in IgG levels poses a challenge to achieving optimal protection [3,47]. IgM antibodies offer short-term protection in the early phase, and neutralising antibodies is vital in preventing symptomatic CHIKV infection by identifying specific epitopes on CHIKV glycoproteins [48,49].…”

Section: Immunology Of Chikungunya Virusmentioning

confidence: 99%

“…2 real-time PCR identification of viral RNA and serological analysis for the existence of IgM and IgG antibodies forms the basis of laboratory diagnosis of CHIKV infection [3]. Treatment of CHIKV infection involves anti-inflammatory drugs and analgesics, which are inadequate [4].…”

Section: Introductionmentioning

confidence: 99%

“…The E1 and E2 glycoproteins regulate the entry of viruses into host cells; E1 is involved in the fusion of the virus with the cell membrane, whereas E2 interacts with the receptors on cells and aids in cell attachment [4,7,8]. The E2 glycoprotein has been identified as the primary target for the anti-CHIKV antibody response throughout the illness [3].…”

Section: Introductionmentioning

confidence: 99%

“…Besides mouse monoclonal antibodies, few reports have shown the development of human monoclonal antibodies and their role in protection against CHIKV infection. Scientists also developed Env-specific anti-CHIKV monoclonal antibodies for prophylactic and therapeutic measures against CHIKV infection [3,11]. There is enough evidence in the literature regarding immunogenic epitopes recognised by protective monoclonal antibodies.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Chikungunya Virus Vaccine: An Update Review

Shaikh,

Faiyazuddin,

Khan

et al. 2024

Preprint

View full text Add to dashboard Cite

Chikungunya virus (CHIKV), a single-stranded RNA virus transmitted by Aedes mosquitoes, poses a significant global health threat, with severe complications observed in vulnerable populations. The only licensed vaccine, IXCHIQ, approved by the USFDA, is insufficient to address the growing disease burden, particularly in endemic regions lacking herd immunity. Monoclonal antibodies (mAbs), explicitly targeting structural proteins E1/E2, demonstrate promise in passive transfer studies, with mouse and human-derived mAbs showing protective efficacy. The article explores various vaccine candidates, including live attenuated, killed, nucleic-acid-based (DNA/RNA), virus-like particle, chimeric, subunit, and adenovirus vectored vaccines. RNA vaccines emerge as promising candidates due to their rapid response capabilities and enhanced safety profile. The review underscores the importance of E1 and E2 proteins as immunogens, emphasising their antigenic potential. Several vaccine candidates, such as CHIKV/IRES, measles vector (MV-CHIK), synthetic DNA-encoded antibodies, and mRNA-lipid nanoparticle vaccines, demonstrate encouraging preclinical and clinical study results. In addition to identifying potential molecular targets for antiviral therapy, the study looks into the roles played by Toll-like receptors, RIG-I, and NOD-like receptors in the immune response to CHIKV. It also offers insights into novel tactics and promising vaccine candidates.

show abstract

An overview of anti-Chikungunya antibody response in natural infection and vaccine-mediated immunity, including anti-CHIKV vaccine candidates and monoclonal antibodies targeting diverse epitopes on the viral envelope

Cited by 2 publications

References 170 publications

Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials

Immunogenicity, safety and duration of protection afforded by chikungunya virus vaccines undergoing human clinical trials

Chikungunya Virus Vaccine: An Update Review

Contact Info

Product

Resources

About